glibenclamide Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96
    Millipore glibenclamide
    <t>Glibenclamide</t> reduces TNF-α while enhances IL-10 production from monocytes in response to BCG and M. tuberculosis . Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide (GB, 25, 50 μM) for 30 min., incubated with 10 5 CFU per well of BCG; or monocytes from UK (n = 5) and Thai (n = 5) healthy individuals were treated with glibenclamide and incubated with M. tuberculosis at 10 5 CFU per well (Mtb). After incubation for 96 h, supernatants were collected for (A) TNF-α and (B) IL-10 detection. Statistical analysis was performed using One Way ANOVA or paired t-test for BCG or Mtb infected samples, respectively. Each bar is expressed as median of each group and each dot represents each sample. ** P
    Glibenclamide, supplied by Millipore, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glibenclamide/product/Millipore
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    glibenclamide - by Bioz Stars, 2022-10
    96/100 stars
      Buy from Supplier

    99
    Thermo Fisher er tracker red
    <t>Glibenclamide</t> reduces TNF-α while enhances IL-10 production from monocytes in response to BCG and M. tuberculosis . Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide (GB, 25, 50 μM) for 30 min., incubated with 10 5 CFU per well of BCG; or monocytes from UK (n = 5) and Thai (n = 5) healthy individuals were treated with glibenclamide and incubated with M. tuberculosis at 10 5 CFU per well (Mtb). After incubation for 96 h, supernatants were collected for (A) TNF-α and (B) IL-10 detection. Statistical analysis was performed using One Way ANOVA or paired t-test for BCG or Mtb infected samples, respectively. Each bar is expressed as median of each group and each dot represents each sample. ** P
    Er Tracker Red, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/er tracker red/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    er tracker red - by Bioz Stars, 2022-10
    99/100 stars
      Buy from Supplier

    99
    Thermo Fisher er tracker
    <t>Glibenclamide</t> reduces TNF-α while enhances IL-10 production from monocytes in response to BCG and M. tuberculosis . Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide (GB, 25, 50 μM) for 30 min., incubated with 10 5 CFU per well of BCG; or monocytes from UK (n = 5) and Thai (n = 5) healthy individuals were treated with glibenclamide and incubated with M. tuberculosis at 10 5 CFU per well (Mtb). After incubation for 96 h, supernatants were collected for (A) TNF-α and (B) IL-10 detection. Statistical analysis was performed using One Way ANOVA or paired t-test for BCG or Mtb infected samples, respectively. Each bar is expressed as median of each group and each dot represents each sample. ** P
    Er Tracker, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/er tracker/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    er tracker - by Bioz Stars, 2022-10
    99/100 stars
      Buy from Supplier

    91
    Thermo Fisher er tracker red bodipy tr glibenclamide
    <t>Glibenclamide</t> reduces TNF-α while enhances IL-10 production from monocytes in response to BCG and M. tuberculosis . Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide (GB, 25, 50 μM) for 30 min., incubated with 10 5 CFU per well of BCG; or monocytes from UK (n = 5) and Thai (n = 5) healthy individuals were treated with glibenclamide and incubated with M. tuberculosis at 10 5 CFU per well (Mtb). After incubation for 96 h, supernatants were collected for (A) TNF-α and (B) IL-10 detection. Statistical analysis was performed using One Way ANOVA or paired t-test for BCG or Mtb infected samples, respectively. Each bar is expressed as median of each group and each dot represents each sample. ** P
    Er Tracker Red Bodipy Tr Glibenclamide, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/er tracker red bodipy tr glibenclamide/product/Thermo Fisher
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    er tracker red bodipy tr glibenclamide - by Bioz Stars, 2022-10
    91/100 stars
      Buy from Supplier

    Image Search Results


    Glibenclamide reduces TNF-α while enhances IL-10 production from monocytes in response to BCG and M. tuberculosis . Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide (GB, 25, 50 μM) for 30 min., incubated with 10 5 CFU per well of BCG; or monocytes from UK (n = 5) and Thai (n = 5) healthy individuals were treated with glibenclamide and incubated with M. tuberculosis at 10 5 CFU per well (Mtb). After incubation for 96 h, supernatants were collected for (A) TNF-α and (B) IL-10 detection. Statistical analysis was performed using One Way ANOVA or paired t-test for BCG or Mtb infected samples, respectively. Each bar is expressed as median of each group and each dot represents each sample. ** P

    Journal: Frontiers in Immunology

    Article Title: Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization

    doi: 10.3389/fimmu.2018.02109

    Figure Lengend Snippet: Glibenclamide reduces TNF-α while enhances IL-10 production from monocytes in response to BCG and M. tuberculosis . Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide (GB, 25, 50 μM) for 30 min., incubated with 10 5 CFU per well of BCG; or monocytes from UK (n = 5) and Thai (n = 5) healthy individuals were treated with glibenclamide and incubated with M. tuberculosis at 10 5 CFU per well (Mtb). After incubation for 96 h, supernatants were collected for (A) TNF-α and (B) IL-10 detection. Statistical analysis was performed using One Way ANOVA or paired t-test for BCG or Mtb infected samples, respectively. Each bar is expressed as median of each group and each dot represents each sample. ** P

    Article Snippet: Monocyte stimulation and cytokine measurement Unless stated otherwise, purified monocytes at a concentration 2.5 × 105 cells/ml in RPMI 1640 culture medium were pretreated with 50 μM glibenclamide (Sigma) [comparable to the peak human plasma concentration achieved following a 20 mg oral dose ( )] for 30 min and then infected with live Mtb or BCG at 102 or 105 CFU per well or activated with 10 μg/ml of LPS (from Escherichia coli, Sigma) at 37°C for 96 h. The supernatants were stored at −80°C until cytokines were measured.

    Techniques: Incubation, Infection

    Glibenclamide reduces M1 but enhances M2 markers on human monocytes. Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide [GB, 0 (vehicle, DMSO), 25, 50 μM] for 30 min. Drug-treated monocytes were incubated with 100 CFU of BCG or RPMI medium (Med) for 96 h and then analyzed M1 and M2 markers by flow cytometry. (A) After exclusion of debris and doublets, monocytes were detected as CD14 + CD16 − and CD14 + CD16 + populations and then further analyzed for M1 (HLA-DR + and CD86 + ) and M2 (CD163 + and CD206 + ) expression, respectively. These data are representative of a healthy individual. (B) The percentage of M1 or M2 positive cells for each individual are shown. Each bar represents the median of each group and each dot represents the value of each sample. Statistical analysis was performed using One Way ANOVA to compare all groups, *** P

    Journal: Frontiers in Immunology

    Article Title: Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization

    doi: 10.3389/fimmu.2018.02109

    Figure Lengend Snippet: Glibenclamide reduces M1 but enhances M2 markers on human monocytes. Monocytes from UK healthy individuals (n = 10) were treated with glibenclamide [GB, 0 (vehicle, DMSO), 25, 50 μM] for 30 min. Drug-treated monocytes were incubated with 100 CFU of BCG or RPMI medium (Med) for 96 h and then analyzed M1 and M2 markers by flow cytometry. (A) After exclusion of debris and doublets, monocytes were detected as CD14 + CD16 − and CD14 + CD16 + populations and then further analyzed for M1 (HLA-DR + and CD86 + ) and M2 (CD163 + and CD206 + ) expression, respectively. These data are representative of a healthy individual. (B) The percentage of M1 or M2 positive cells for each individual are shown. Each bar represents the median of each group and each dot represents the value of each sample. Statistical analysis was performed using One Way ANOVA to compare all groups, *** P

    Article Snippet: Monocyte stimulation and cytokine measurement Unless stated otherwise, purified monocytes at a concentration 2.5 × 105 cells/ml in RPMI 1640 culture medium were pretreated with 50 μM glibenclamide (Sigma) [comparable to the peak human plasma concentration achieved following a 20 mg oral dose ( )] for 30 min and then infected with live Mtb or BCG at 102 or 105 CFU per well or activated with 10 μg/ml of LPS (from Escherichia coli, Sigma) at 37°C for 96 h. The supernatants were stored at −80°C until cytokines were measured.

    Techniques: Incubation, Flow Cytometry, Cytometry, Expressing

    Effect of different DM treatment regimens on broad cytokine production in response to M. tuberculosis . Four Thai groups are shown including healthy controls and diabetic individuals who have been treated with glibenclamide (GB), glipizide (GP), or metformin (Met). Purified monocytes from each group were infected with (A) M. tuberculosis at 10 5 CFU per well (Mtb) or stimulated with (B) 10 μg/ml of E. coli LPS. Due to limited blood volume, some samples were not stimulated with LPS. After incubated at 96 h, supernatants were collected and kept in −80°C prior to cytokine detection. TNF-α, IL-10, and IL-6 were detected by ELISA and IL-8, MCP-1 and RANTES were detected by CBA. Each bar is expressed as median with interquartile range of each group and each dot represents each sample. The number of individuals tested are shown in parentheses. Asterisks indicate significant differences between all individual groups by One Way ANOVA. **** P

    Journal: Frontiers in Immunology

    Article Title: Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization

    doi: 10.3389/fimmu.2018.02109

    Figure Lengend Snippet: Effect of different DM treatment regimens on broad cytokine production in response to M. tuberculosis . Four Thai groups are shown including healthy controls and diabetic individuals who have been treated with glibenclamide (GB), glipizide (GP), or metformin (Met). Purified monocytes from each group were infected with (A) M. tuberculosis at 10 5 CFU per well (Mtb) or stimulated with (B) 10 μg/ml of E. coli LPS. Due to limited blood volume, some samples were not stimulated with LPS. After incubated at 96 h, supernatants were collected and kept in −80°C prior to cytokine detection. TNF-α, IL-10, and IL-6 were detected by ELISA and IL-8, MCP-1 and RANTES were detected by CBA. Each bar is expressed as median with interquartile range of each group and each dot represents each sample. The number of individuals tested are shown in parentheses. Asterisks indicate significant differences between all individual groups by One Way ANOVA. **** P

    Article Snippet: Monocyte stimulation and cytokine measurement Unless stated otherwise, purified monocytes at a concentration 2.5 × 105 cells/ml in RPMI 1640 culture medium were pretreated with 50 μM glibenclamide (Sigma) [comparable to the peak human plasma concentration achieved following a 20 mg oral dose ( )] for 30 min and then infected with live Mtb or BCG at 102 or 105 CFU per well or activated with 10 μg/ml of LPS (from Escherichia coli, Sigma) at 37°C for 96 h. The supernatants were stored at −80°C until cytokines were measured.

    Techniques: Purification, Infection, Incubation, Enzyme-linked Immunosorbent Assay, Crocin Bleaching Assay

    Glibenclamide treatment impairs killing of M. tuberculosis by monocytes. (A) Monocytes from UK healthy individuals were treated with glibenclamide (GB, 50, 100 μM) for 30 min. Drug-treated monocytes were incubated with 10 2 CFU per well of M. tuberculosis (Mtb, n = 9) or BCG (n = 5) for 96 h and then the total bacteria were collected for MGIA. (B) Purified monocytes from four Thai individual groups shown as healthy control (n = 9) and diabetic individuals who have been treated with glibenclamide (GB, n = 9), glipizide (GP, n = 10), or metformin (Met, n = 11) were infected with 10 2 CFU of M. tuberculosis for 96 h and total bacteria were determined by MGIA. Statistical analysis was performed using One Way ANOVA to compare between control and other groups. Data are expressed as median with interquartile range. *** P

    Journal: Frontiers in Immunology

    Article Title: Glibenclamide Reduces Primary Human Monocyte Functions Against Tuberculosis Infection by Enhancing M2 Polarization

    doi: 10.3389/fimmu.2018.02109

    Figure Lengend Snippet: Glibenclamide treatment impairs killing of M. tuberculosis by monocytes. (A) Monocytes from UK healthy individuals were treated with glibenclamide (GB, 50, 100 μM) for 30 min. Drug-treated monocytes were incubated with 10 2 CFU per well of M. tuberculosis (Mtb, n = 9) or BCG (n = 5) for 96 h and then the total bacteria were collected for MGIA. (B) Purified monocytes from four Thai individual groups shown as healthy control (n = 9) and diabetic individuals who have been treated with glibenclamide (GB, n = 9), glipizide (GP, n = 10), or metformin (Met, n = 11) were infected with 10 2 CFU of M. tuberculosis for 96 h and total bacteria were determined by MGIA. Statistical analysis was performed using One Way ANOVA to compare between control and other groups. Data are expressed as median with interquartile range. *** P

    Article Snippet: Monocyte stimulation and cytokine measurement Unless stated otherwise, purified monocytes at a concentration 2.5 × 105 cells/ml in RPMI 1640 culture medium were pretreated with 50 μM glibenclamide (Sigma) [comparable to the peak human plasma concentration achieved following a 20 mg oral dose ( )] for 30 min and then infected with live Mtb or BCG at 102 or 105 CFU per well or activated with 10 μg/ml of LPS (from Escherichia coli, Sigma) at 37°C for 96 h. The supernatants were stored at −80°C until cytokines were measured.

    Techniques: Incubation, Purification, Infection